BELLUS Health Updates BLU-5937 Top-Line Phase 1 Results Timeline to November 2018
(WorldNews Health)

- Reports Financial and Operating Results for the Third Quarter Ended September 30, 2018 - LAVAL, QC, Nov. 14, 2018 /CNW/ - BELLUS Health Inc. (TSX: BLU) (`BELLUS Health` or the `Company`), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today updated the top-line phase 1 results timeline to November 2018 for its lead drug candidate BLU-5937 for chronic cough. The Company also reported its financial and operating results for the third quarter ended September 30, 2018. All currency figures reported in this press release are in Canadian dollars, unless otherwise specified. Recent Highlights Expects by the end of November...